Shoshana Shendelman

Shoshana Shendelman
Alma mater	Columbia University
Known for	Founder of Applied Therapeutics
Website	https://drshendelman.com/

Shoshana Shendelman is an American scientist and founder of several biotech companies. ^[1] She is a vice chair for the Board of Advisors at Columbia University Irving Medical Center and Columbia University Vagelos College of Physicians and Surgeons. ^[2]

Education

Shendelman received a BA in biochemistry from Brandeis University. She received a PhD from Columbia University Vagelos College of Physicians and Surgeons' Integrated Program in Cellular, Molecular and Biophysical Studies, where she also completed her master's degrees (both an MA and MSc). Dr. Shendelman's neurobiological research at Columbia focused on molecular mechanisms driving neurodegenerative diseases. Her doctoral thesis, in the laboratory of Asa Abeliovich, MD, PhD, centered around molecular mechanisms of Parkinson's disease. ^{[3] [4] [5]}

Career

In 2012, Shendelman founded Clearpoint Strategy Group, a boutique life sciences consulting firm where she served as managing director. ^[6]

In 2016, she founded Applied Therapeutics, a biopharmaceutical company committed to developing treatments for rare diseases. Applied Therapeutics publicly listed on the NASDAQ under the symbol APLT in 2019. ^[7] In 2024, Shendelman left the company after shareholders filed a class action lawsuit against her alleging securities fraud. ^{[8] [9] [10]}

In 2025, Shendelman founded Cyana Therapeutics, a precision immuno-oncology company developing drugs to treat solid tumors. ^[11]

In 2020, Shendelman was appointed to the Board of Advisors at Columbia University Irving Medical Center and Columbia University Vagelos College of Physicians and Surgeons, later being named vice chair of the b by P. Roy Vagelos. In 2023, Shendelman joined the Trustees of Columbia University in the City of New York. ^[12]

References

1. "Shoshana Shendelman". Forbes. Retrieved July 7, 2025.
2. "Shoshana Shendelman | Office of the Secretary". secretary.columbia.edu. Retrieved July 7, 2025.
3. "Shoshana Shendelman | Office of the Secretary". secretary.columbia.edu. Retrieved July 7, 2025.
4. Shendelman, Shoshana; Jonason, Alan; Martinat, Cecile; Leete, Thomas; Abeliovich, Asa (October 5, 2004). "DJ-1 Is a Redox-Dependent Molecular Chaperone That Inhibits α-Synuclein Aggregate Formation". PLOS Biology. 2 (11): e362. doi: 10.1371/journal.pbio.0020362 . PMC   521177 . PMID   15502874.
5. Martinat, Cecile; Shendelman, Shoshana; Jonason, Alan; Leete, Thomas; Beal, M. Flint; Yang, Lichuan; Floss, Thomas; Abeliovich, Asa (October 5, 2004). "Sensitivity to Oxidative Stress in DJ-1-Deficient Dopamine Neurons: An ES-Derived Cell Model of Primary Parkinsonism". PLOS Biology. 2 (11): e327. doi: 10.1371/journal.pbio.0020327 . PMC   521171 . PMID   15502868.
6. "Kikka Hanazawa and Shoshana Shendelman Join Trustees | Columbia Magazine". magazine.columbia.edu. Retrieved July 7, 2025.
7. "Form S-1 Registration Statement". U.S. Securities and Exchange Commission. April 12, 2019. Retrieved December 9, 2025.
8. Walton, Meghnad Bose, Lara-Nour (May 27, 2025). "Columbia Trustee Got Sued for Securities Fraud — Then Left Her Pharma Firm Under a Cloud". The Intercept. Retrieved December 12, 2025.
9. Incorvaia, Darren (December 20, 2024). "After investors file lawsuit, Applied CEO steps down". www.fiercebiotech.com. Retrieved December 12, 2025.
10. Feuerstein, Adam (December 5, 2024). "Why Applied Therapeutics has a credibility problem". STAT. Retrieved December 12, 2025.
11. "Shoshana Shendelman, PhD Co-Founder and CEO". Cyana Therapeutics. Retrieved December 9, 2025.
12. "Kikka Hanazawa, GS '00, and Shoshana Shendelman, VP&S '05, join Columbia Board of Trustees". Columbia Daily Spectator. Retrieved December 9, 2025.